Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Cited by (1,000)

Items 601–700 of 1,000

1. The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma
   Dinja Oosterhoff, Berbel J.R. Sluijter, Basav N. Hangalapura, Tanja D. de Gruijl · 2011 · Current topics in microbiology and immunology
2. Management of pulmonary toxicity associated with targeted anticancer therapies
   Laure-Anne Marie Nicole Teuwen, Tom Van den Mooter, Luc Yves Dirix · 2015 · Expert Opinion on Drug Metabolism & Toxicology
3. Future directions in tumor immunotherapy: CTLA4 blockade
   James L. Gulley, William L. Dahut · 2007 · Nature Clinical Practice Oncology
4. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma
   Seiichi Yano, Kenji Ashida, Hiromi Nagata, Kenji Ohe, Naoko A. Wada, Yukina Takeichi, Yuki Hanada, Yuta Ibayashi, Lixiang Wang, Shohei Sakamoto et al. · 2018 · BMC Endocrine Disorders
5. Therapeutic potential of immunostimulatory monoclonal antibodies
   Juliet C. Gray, Peter Johnson, Martin J. Glennie · 2006 · Clinical Science
6. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies
   Jeffrey S. Weber · 2006 · Melanoma Research
7. Evaluation of Expression of LRBA and CTLA-4 Proteins in Common Variable Immunodeficiency Patients
   Fereshte Salami, Saba Fekrvand, Reza Yazdani, Sepideh Shahkarami, Gholamreza Azizi, Yasser Bagheri, Samaneh Delavari, Sahar Shariati, Seyed Alireza Mahdaviani, Mohammamd Nabavi et al. · 2020 · Immunological Investigations
8. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis
   Ruiyi Deng, Hua Zhang, Yuan Li, Yanyan Shi · 2022 · Journal of Immunotherapy
9. NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment
   Nassima Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, Immanuel F. Luescher, Danijel Dojcinovic, Jean‐Marc Classe, Dominique Berton-Rigaud, Jean‐Sébastien Frenel, Emmanuelle Bourbouloux, Danila Valmori et al. · 2011 · PLoS ONE
10. New Therapeutic Options in the Medical Management of Advanced Melanoma
    Jose Lutzky · 2010 · Seminars in Cutaneous Medicine and Surgery
11. Tlr7 Agonist in Combination With Salmonella as an Effective Antimelanoma Immunotherapy
    Magdalena Vola, Amy Mónaco, Thais Bascuas, Geraldine Rimsky, Caroline Agorio, Jose Alejandro Chabalgoity, Marı́a Moreno · 2018 · Immunotherapy
12. The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity
    Shin Foong Ngiow, Bianca von Scheidt, Andreas Möller, Mark John Smyth, Michele W.L. Teng · 2013 · OncoImmunology
13. Surveillance of the Eye and Vision in Clinical Trials of CP-675,206 for Metastatic Melanoma
    Bradley R. Straatsma, Steven Nusinowitz, Tara A. Young, Lynn K. Gordon, Melissa W. Chun, Colleen Rosen, Elisabeth Seja, James S. Economou, John A. Glaspy, Viviana A. Bozon et al. · 2007 · American Journal of Ophthalmology
14. Updates in Immunotherapy for Pancreatic Cancer
    Robert Connor Chick, Timothy Michael Pawlik · 2024 · Journal of Clinical Medicine
15. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)
    Tibor Bakács, Jitendra N. Mehrishi, Miklós Szabó, Ralph W. Moss · 2012 · Pharmacological Research
16. Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
    Elisabetta Pennacchioli, Giulio Tosti, Emilia Cocorocchio · 2013 · Clinical Cosmetic and Investigational Dermatology
17. Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas
    Robert V. Rawson, Elizabeth Robbins, Rony Kapoor, Richard A. Scolyer, Georgina Venetia Long · 2017 · European Journal of Cancer
18. Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors
    STEPHAN R. THURAU, Hendrik Engelke, Peter McCluskey, Richard J. Symes, Eline Whist, Barbara Teuchner, Gertrud Haas, Pia Allegri, Luca Cimino, Elena Bolletta et al. · 2021 · Ocular Immunology and Inflammation
19. Thoracic metastasectomy for adoptive immunotherapy of melanoma: A single-institution experience
    Jacob A. Klapper, Jeremy L. Davis, Robert Taylor Ripley, Franz Omar Smith, Dao M. Nguyen, King F. Kwong, Leandro Mercedes, Clinton D. Kemp, Aarti Mathur, Donald Edward White et al. · 2010 · Journal of Thoracic and Cardiovascular Surgery
20. Immunotherapy of Melanoma
    Petra Rietschel, Paul B. Chapman · 2006 · Hematology/Oncology Clinics of North America
21. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy
    Arjun Gupta, Udayan Shah, Htet Khine, Travis W. Vandergriff, Thomas W. Froehlich · 2017 · Melanoma Research
22. Hypophysitis Induced by Immune Checkpoint Inhibitors in a Scottish Melanoma Population
    Khor Zhong Wei, Mark A Baxter, Richard Casasola · 2019 · Melanoma Management
23. Recent Advances in Immunotherapy for Melanoma: Perspectives on the Development of Novel Treatments: A Mini Review
    Yusuke Muto, Taku Fujimura, Yoshihide Asano · 2025 · Cancers
24. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity
    Scott C. Bresler, Le Min, Scott J. Rodig, Andrew C Walls, Shuyun Xu, Songmei Geng, Frank Stephen Hodi, Gëorge F. Murphy, Christine Guo Lian · 2016 · Laboratory Investigation
25. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
    Edyta Żyła, Bogdan Musielak, Tad A. Holak, Grzegorz Dubin · 2021 · Molecules
26. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances
    Xiang Wang, Zijun Yuan, Zhengbo Li, Xinyu He, Yinping Zhang, Xingyue Wang, Jiahong Su, Xu Wu, Mingxing Li, Fukuan Du et al. · 2024 · Frontiers in Immunology
27. Melanoma Immunotherapy
    Shanthi Sivendran, Bradley Glodny, Michael M. Pan, Miriam Mérad, Yvonne M. Saenger · 2010 · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine
28. Tumors, tumor therapies, autoimmunity and the eye
    Gerhild Wildner · 2021 · Autoimmunity Reviews
29. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
    Grazia Graziani, Lucia Lisi, Lucio Tentori, Pierluigi Navarra · 2022 · Experientia supplementum
30. Skin manifestations associated with checkpoint inhibitors
    Gianluca Nazzaro, Stefano Buffon, Serena Giacalone, Carlo Alberto Maronese, Angelo Valerio Marzano · 2022 · JEADV Clinical Practice
31. Immunothérapie des cancers
    Éric Tartour, Federico Sandoval, Jean‐Yves Bonnefoy, Wolf H. Fridman · 2011 · médecine/sciences
32. The Ubiquitin E3 Ligase Cbl-b in T Cells Tolerance and Tumor Immunity
    Stefanie Loeser, Josef Martin Penninger · 2007 · Cell Cycle
33. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
    Nicola Silvestris, Antonella Argentiero, Giordano Domenico Beretta, Paolo Di Bartolo, Monica Montagnani, Romano Danesi, Pietro Ferrari, Stella D’Oronzo, Stefania Gori, Antonio Dello Russo et al. · 2020 · Critical Reviews in Oncology/Hematology
34. Oncophage®(vitespen®) - Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?
    Alessandra di Pietro, Giulio Tosti, Pier Francesco Ferrucci, Alessandro Testori · 2009 · Human Vaccines
35. Focus on FOCIS: Interleukin 2 treatment associated autoimmunity
    Stergios J. Moschos, Maja Mandić, John M. Kirkwood, Walter J. Storkus, Michael T. Lotze · 2008 · Clinical Immunology
36. Checkpoint inhibitors in H odgkin's lymphoma
    Barbara Jezeršek Novaković · 2015 · European Journal Of Haematology
37. Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis
    Lucheng Zhu, Saisai Jing, Bing Wang, Kan Wu, Ma Shenglin, Shirong Zhang · 2015 · Pathology & Oncology Research
38. Application of immune repertoire sequencing in cancer immunotherapy
    Yuan Zhuang, Changzheng Zhang, Qiong Wu, Jing Zhang, Zhenlong Ye, Qijun Qian · 2019 · International Immunopharmacology
39. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features
    Sara Esteves-Ferreira, Patrícia Mendonça Oliveira Rosinha · 2023 · Journal of Cancer Research and Clinical Oncology
40. Cancer vaccines: up, down, … up again?
    Sattva Swarup Neelapu, Larry W. Kwak · 2009 · Blood
41. Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response
    Bo Wang, Xuanyi Wang, Yu‐Mei Wen, Jing Fu, Hongyang Wang, Zhang‐Mei Ma, Yan Shi, Bin Wang · 2015 · Scientific Reports
42. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization
    Johanna Rausch, Pamela Aranda Lopez, Ariane Bialojan, Mark Denny, Peter Langguth, Hans Christian Probst, Hansjörg Schild, Markus Philipp Radsak · 2017 · Journal of Dermatological Science
43. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age
    Krishna Prasad Joshi, Dinesh Atwal, Rahul Ravilla, Yadav Pandey, Naveen Yarlagadda, Sunilkumar Kakadia, Issam Makhoul, Laura Fulper Hutchins, Fade Aziz Mahmoud · 2020 · The Permanente Journal
44. Trends in Cancer Immunotherapy
    Joseph F. Murphy · 2010 · Clinical Medicine Insights Oncology
45. Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
    Rebecca Karp Leaf, Jodi Victoria Mones, Tushar Shenoy, Mohamed Warsame, Marina Beltrami Moreira, Sandhya Panch, Andrew D. Leavitt, Rebecca L. Zon, Ellen K. Kendall, Sahar Shahamatdar et al. · 2025 · Blood
46. Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
    Evan Rosenbaum P. E, Kenneth P. Seier, Martina Bradić, Ciara Marie Kelly, Sujana Movva, Benjamin Alexander Nacev, Mrinal M. Gounder, Mary Louise Keohan, Viswatej Avutu, Ping Chi et al. · 2023 · Cancer Research Communications
47. The Use of Analgesics during Vaccination with a Live Attenuated Yersinia pestis Vaccine Alters the Resulting Immune Response in Mice
    Marilynn J. Culbreth, Sergei S. Biryukov, Jennifer L. Shoe, Jennifer L. Dankmeyer, Melissa Hunter, Christopher P. Klimko, Raysa Rosario-Acevedo, David P. Fetterer, Alicia M. Moreau, Susan L. Welkos et al. · 2019 · Vaccines
48. Assessing Treatment Benefit in Immuno-oncology
    M. Buyse, E. Saad, T. Burzykowski, J. Péron · 2020 · Statistics in Biosciences
49. Nivolumab and Ipilimumab Immunotherapy for Hemodialysis Patients with Advanced Renal Cell Carcinoma
    Yukari Kobayashi, H. Arai, Masashi Honda · 2020 · Current Oncology
50. Influence of human immune cells on cancer: studies at the University of Colorado
    Tullia Carmela Bruno, Jena D. French, Kimberly Rae Jordan, Oscar Ramirez, Trisha R. Sippel, Virginia F. Borges, Bryan R. Haugen, Martin D. McCarter, Allen E. Waziri, Jill E. Slansky · 2012 · Immunologic Research
51. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer
    Tetje Cornelia van der Sluis, Sjoerd H. van der Burg, Ramon Arens, Cornelis J.M. Melief · 2015 · Current Opinion in Immunology
52. Atypical Clinical Response Patterns to Ipilimumab
    Blanca A. Ledezma, Sandra Binder, Omid Hamid · 2011 · Clinical journal of oncology nursing
53. Harnessing Immune Checkpoints for Cancer Therapy
    Dass S. Vinay, Byoung Se Kwon · 2018 · Immunotherapy
54. Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre
    Iñigo Gonzalez-Mazón, Lara Sánchez-Bilbao, J. L. Martín-Varillas, Almudena García‐Castaño, Marina Delgado Ruiz, Isabel Bernat Piña, José L. Hernández, Santos Castañeda, Javier Llorca, Miguel Ángel González-Gay et al. · 2021 · Clinical and Experimental Rheumatology
55. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities
    Stergios Boussios, Matin Sheriff, Elie Rassy, Michele Moschetta, Eleftherios Pierre Samartzis, Rachel Hallit, Agne Sadauskaite, Konstantinos H. Katsanos, Dimitrios K. Christodoulou, Nicholas A. Pavlidis · 2021 · Annals of Translational Medicine
56. Systemic treatment of metastatic melanoma: New approaches
    Omid Hamid, Peter D. Boasberg, Katherine Rosenthal, Steven J O'Day · 2011 · Journal of Surgical Oncology
57. Occurrence of Autoimmunity in a Long-Term Survivor with Metastatic Colon Carcinoma Treated with a New Chemo-Immunotherapy Regimen
    Pierpaolo Correale, Antonella Fioravanti, Innocenzo Bertoldi, F. Montagnani, Clelia Miracco, Guido Francini · 2008 · Journal of Chemotherapy
58. Immunotherapy for malignant mesothelioma: reality check
    Bibhusal Thapa, D. Neil Watkins, Tom John · 2016 · Expert Review of Anticancer Therapy
59. Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System
    Qingli Kong, Hui Wang, Xiaolei Ren, Yue Zhuo, Jing Peng · 2023 · Cancer Medicine
60. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients
    Reyhan Amode, Barouyr Baroudjian, Anita Kowal, Majdi Jebali, Clara Allayous, Martine Bagot, Nika Madjlessi, Jennifer Roux, Manuelle A Viguier, Nicole Basset‐Séguin et al. · 2016 · Melanoma Research
61. The importance of establishing genetic phase in clinical medicine
    Brian D. Tait · 2021 · International Journal of Immunogenetics
62. Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure
    Kathryn Ries Tringale, Anne S. Reiner, Ryka R. Sehgal, Katherine S. Panageas, Allison Betof Warner, Michael Andrew Postow, Nelson S. Moss · 2023 · CNS Oncology
63. Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC)
    Petr G. Lokhov, Elena E. Balashova · 2015 · Human Vaccines & Immunotherapeutics
64. Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro
    Petr G. Lokhov, Elena E. Balashova · 2013 · Human Vaccines & Immunotherapeutics
65. Functionality of Patients 75 Years and Older Undergoing Mohs Micrographic Surgery: A Multicenter Study
    Christie G. Regula, Murad Alam, Ramona Behshad, Marc Glashofer, C. William Hanke, Christopher B. Harmon, Ryan P. Johnson, David E. Kent, Patrick S. Y. Lee, Naomi Lawrence · 2017 · Dermatologic Surgery
66. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy
    Carlo Pincelli, Marco Pignatti, Riccardo G. Borroni · 2009 · Experimental Dermatology
67. T Cell Tolerance to Tumors and Cancer Immunotherapy
    Kimberly Shafer-Weaver, Michael J. M. Anderson, Anatoli M. Malyguine, Arthur A. Hurwitz · 2007 · Advances in experimental medicine and biology
68. Application of Immune Checkpoint Inhibitors in Cancer
    Zhijun Chen, Zihan Song, Shichen Den, Wei Zhang, Mengjia Han, Tianhang Lan, Xiaokang Du, J Ning, XinHui Chen, Haoming Lin et al. · 2025 · MedComm
69. New targeted therapies in the treatment of patients with metastatic melanoma
    Jacek Mackiewicz, Łukasz Kwinta · 2010 · Współczesna Onkologia
70. Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010)
    Laura Ridolfi, Ruggero Ridolfi · 2009 · Expert Review of Dermatology
71. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events
    Machiko Kawahira, Shuji Kanmura, Keiko Mizuno, Kentaro Machida, Takao Ohtsuka, Masami Sato, Hideki Enokida, Masaru Yamashita, Takuro Kanekura, Shiho Arima et al. · 2022 · PLoS ONE
72. Ipilimumab-related orbitopathy: a case report
    Abigail P. Jebaraj, Tyler J. Etheridge, Blair A. Winegar, Douglas P. Marx · 2022 · Orbit
73. Chimeric Antigen Receptor T Cells for the Treatment of Cancer and the Future of Preclinical Models for Predicting their Toxicities
    Anja Wegner · 2017 · Immunotherapy
74. Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune‐related adverse events after immune checkpoint inhibitor therapy
    Nikki Burdett, Kristin Hsu, Libo Xiong, Gonzalo Tapia Rico, Kerri Beckmann, Christos Stelios Karapetis, Michael Paul Brown · 2019 · Asia-Pacific Journal of Clinical Oncology
75. Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD1‐Antikörper beim metastasierten Melanom
    Katharina Charlotte Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Rotraut Mößner, Selma Ugurel, Lisa Zimmer, Ralf Gutzmer, für das Komitee „Kutane Nebenwirkungen“ der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) · 2016 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
76. Phase I Trial of an Enhanced Prostate-Specific Antigen–Based Vaccine and Anti–CTLA-4 Antibody in Patients with Metastatic Androgen-Independent Prostate Cancer
    Marc Robert Theoret, Philip Martin Arlen, Mary P. Pazdur, William L. Dahut, Jeffrey Schlom, James L. Gulley · 2007 · Clinical Genitourinary Cancer
77. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma
    S. A. Fateh, Todd D. Schell, Rebecca Gingrich, Rogerio Izar Neves, Joseph J. Drabick · 2010 · Cancer Biology & Therapy
78. CTLA-4 Gene Exon-1 +49 A/G Polymorphism: Lack of Association with Autoimmune Disease in Patients with Common Variable Immune Deficiency
    Adina Kay Knight, Davide Serrano, Yaron Tomer, Charlotte Cunningham‐Rundles · 2006 · Journal of Clinical Immunology
79. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE‐A3 antigen presented by HLA‐A1 molecules
    Eric Michael Bluman, Pierre G. Coulie, Xiaojuan Sun, Jason T. Machan, Chouzao Lin, Patricia A. Meitner, Joel A. Block, Richard M. Terek · 2007 · Journal of Orthopaedic Research®
80. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
    Ben Sprangers · 2007 · Frontiers in bioscience
81. Active immunotherapy for non-small-cell lung cancer: moving toward a reality
    Cesar A. Perez, Edgardo S. Santos, Luis Estuardo Raez · 2011 · Expert Review of Anticancer Therapy
82. Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis
    Julie C. Bulman, Gaurav Khatri, Lori Meril Watumull, Yull Edwin Arriaga, John R. Leyendecker · 2018 · Radiographics
83. Effects of systemic targeted immunosuppressive therapy on ocular surface
    Sabrina Mukhtar, Vishal Jhanji · 2022 · Current Opinion in Ophthalmology
84. Pulmonary Sarcoid–like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma
    Natacha Bordry, Carla Costa-Nunes, Laurène Cagnon, Philippe O. Gannon, Samia Abed‐Maillard, Petra Baumgaertner, Timothy J. Murray, Igor Letovanec, Romain Lazor, Hasna Bouchaab et al. · 2014 · Cancer Immunology Research
85. Long-Lasting Responses under Treatment with Ipilimumab: An Argument against Maintenance Therapy?
    Julika Dick, Alexander Enk, Jessica C. Hassel · 2014 · Dermatology
86. Immunotherapeutic Strategies: The Melanoma Example
    Annelies Jorritsma, Ton N. Schumacher, John B.A.G. Haanen · 2009 · Immunotherapy
87. Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis
    Kelcie Witges, Leigh Anne Shafer, Ryan Zarychanski, Ahmed M Abou-Setta, Rasheda Rabbani, Orvie Dingwall, Charles Noah Bernstein · 2020 · Drug Safety
88. Pulmonary Toxicities of Immunotherapy
    Mehmet Altan, Linda Zhong, Vickie R. Shannon, Ajay Sheshadri · 2021 · Advances in experimental medicine and biology
89. Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review
    Minas Sakellakis, Nikolaos Spathas, Konstantinos T. Tsaousis, Emmanouil N Nikitiadis, Helena Linardou, Vasilios F. Diakonis · 2022 · Cureus
90. Immunologic targeting of the cancer stem cell
    Catherine J. Wu · 2008 · StemBook
91. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study
    Yüksel Ürün, Arzu Yaşar, Hande Turna, Ece Esin, Ali Murat Sedef, Ali Alkan, Berna Çakmak Öksüzoğlu, Nuriye Özdemir, MA Nahit Sendur, Ahmet Sezer et al. · 2018 · Journal of Oncology Pharmacy Practice
92. Targeting Immune Checkpoints in Melanoma: An Update
    Rodrigo Ramella Munhoz, Alejandro Falcón, Vanessa A. Reed, Michael Andrew Postow · 2015 · Melanoma Management
93. Effets secondaires digestifs et hépatiques des inhibiteurs du checkpoint immunitaire (Immune checkpoint inhibitors : anti-CTLA-4 et anti-PD-1/PD-L1) : aspects anatomocliniques
    Barbara Papouin, Charlotte Mussini, Eléonora De Martin, Catherine Guettier · 2018 · Annales de Pathologie
94. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
    Cynthia Nguyen Tran, Hamzah Abu‐Sbeih, Wenyi Luo, Yang Lü, Yinghong Wang · 2019 · Journal of Immunotherapy and Precision Oncology
95. Assessment of Functionality in Elderly Patients When Determining Appropriate Treatment for Nonmelanoma Skin Cancers
    Michael A. Renzi, Matthew D. Belcher, Bruce A. Brod, Preston W. Chadwick, Ashley Decker, Cynthia A. Dolan, Erum N. Ilyas, Anna Magee, Elizabeth I. McBurney, Thomas D. Regan et al. · 2019 · Dermatologic Surgery
96. Molecularly targeted therapy and immunotherapy for hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (Review)
    Yuhua Song, Lin He, Yaling Wang, Qian Wu, Wenzhi Huang · 2020 · Oncology Reports
97. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer
    Nikhil Atul Shukla, Sandra K. Althouse, Zachary Scott Meyer, Nasser H. Hanna, Greg Andrew Durm · 2021 · Clinical Lung Cancer
98. Are radiologists ready to evaluate true response to immunotherapy?
    İnci Kızıldağ Yirgin, Şükrü Mehmet Ertürk, İzzet Doğan, Sezai Vatansever · 2021 · Insights into Imaging
99. Skin Reactions to Immune Checkpoint Inhibitors
    Anisha B. Patel, Omar Pacha · 2021 · Advances in experimental medicine and biology
100. Skin Reactions to Immune Checkpoint Inhibitors
     Anisha B. Patel, Omar Pacha · 2020 · Advances in experimental medicine and biology